Cost-utility of molecular adsorbent recirculating system treatment in acute liver failure  

作　　者：Taru Kantola Suvi Mklin Anna-Maria Koivusalo Pirjo Rsnen Anne Rissanen Risto Roine Harri Sintonen Krister Hckerstedt Helena Isoniemi 

机构地区：[1]Department of Anesthesiology and Intensive Care Medicine,Surgical Hospital of Helsinki [2]Helsinki University Hospital [3]Finnish Office for Health Technology Assessment at the National Institute for Health and Welfare Finland [4]Helsinki and Uusimaa Hospita Group,Group Administration [5]Department of Health Economics,University of Helsinki,Department of Public Health and Finnish Office for Health Technology Assessment,PO Box 41,00014 University of Helsinki [6]Department of Surgery,Transplantation and Liver Surgery Clinic,Helsinki University Hospital [7]Transplantation and Liver Surgery Clinic,Helsinki University Hospital

出　　处：《World Journal of Gastroenterology》2010年第18期2227-2234,共8页世界胃肠病学杂志（英文版）

基　　金：Supported by Scientific grants from the Helsinki University Central Hospital Research Fund (EVO) and the Finnish Office for Health Technology Assessment

摘　　要：AIM:To determine the short-term cost-utility of mo-lecular adsorbent recirculating system(MARS) treatment in acute liver failure(ALF).METHODS:A controlled retrospective study was conducted with 90 ALF patients treated with MARS from 2001 to 2005.Comparisons were made with a historical control group of 17 ALF patients treated from 2000 to 2001 in the same intensive care unit(ICU) specializing in liver diseases.The 3-year outcomes and number of liver transplantations were recorded.All direct liver disease-related medical expenses from 6 mo before to 3 years after ICU treatment were determined for 31 MARS patients and 16 control patients.The health-related quality of life(HRQoL) before MARS treatment was estimated by a panel of ICU doctors and after MARS using a mailed 15D(15-dimensional generic healthrelated quality of life instrument) questionnaire.The HRQoL,cost,and survival data were combined and the incremental cost/quality-adjusted life years(QALYs) was calculated.RESULTS:In surviving ALF patients,the health-related quality of life after treatmeant was generally high and comparable to the age-and gender-matched general Finnish population.Compared to the controls,the average cost per QALY was considerably lower in the MARS group(64 732€ vs 133 858€) within a timeframe of 3.5 years.The incremental cost of standard medical treatment alone compared to MARS was 10 928€,and the incremental number of QALYs gained by MARS was 0.66.CONCLUSION:MARS treatment combined with standard medical treatment for ALF in an ICU setting is more cost-effective than standard medical treatment alone.AIM:To determine the short-term cost-utility of mo-lecular adsorbent recirculating system(MARS) treatment in acute liver failure(ALF).METHODS:A controlled retrospective study was conducted with 90 ALF patients treated with MARS from 2001 to 2005.Comparisons were made with a historical control group of 17 ALF patients treated from 2000 to 2001 in the same intensive care unit(ICU) specializing in liver diseases.The 3-year outcomes and number of liver transplantations were recorded.All direct liver disease-rel...

关 键 词：Albumin dialysis COST-EFFICIENCY Healthrelated quality of life Quality-adjusted life year 

分 类 号：R575.3[医药卫生—消化系统]